NCT06622005View on ClinicalTrials.gov

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 10, 2025

Primary Completion Date

April 10, 2027

Study Completion Date

April 10, 2030

Conditions
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Interventions
DRUG

Cxcr1/2 Inhibitor SX-682

Given PO

DRUG

Daratumumab and Recombinant Human Hyaluronidase

Given SC

DRUG

Carfilzomib

Given IV

DRUG

Dexamethasone

Given PO

PROCEDURE

Biospecimen Collection

Undergo Blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo Bone Marrow Aspiration

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Computed Tomography

Undergo PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT06622005 - SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter